|
Ning, Yang-Min; Figg, William D; Dahut, William L (2009) Reversal of docetaxel resistance with bevacizumab and thalidomide. Clin Genitourin Cancer 7:E37-8
|
|
Ge, Yun; Byun, Jung S; De Luca, Paola et al. (2008) Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol. Mol Pharmacol 74:872-83
|
|
Li, Haiqing; Raia, Valentina; Bertolini, Francesco et al. (2008) Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int 101:884-8
|
|
Li, Haiqing; Price, Douglas K; Figg, William D (2007) ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs 18:563-8
|
|
Lakhani, Nehal J; Sparreboom, Alex; Xu, Xia et al. (2007) Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. J Pharm Sci 96:1821-31
|
|
Gojo, Ivana; Jiemjit, Anchalee; Trepel, Jane B et al. (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109:2781-90
|
|
Sion, Amy M; Figg, William D (2006) Lysyl oxidase (LOX) and hypoxia-induced metastases. Cancer Biol Ther 5:909-11
|
|
Jain, Lokesh; Venitz, Jurgen; Figg, William D (2006) Randomized discontinuation trial of sorafenib (BAY 43-9006). Cancer Biol Ther 5:1270-2
|
|
Dahut, William L; Lakhani, Nehal J; Gulley, James L et al. (2006) Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5:22-7
|
|
Ge, Yun; Montano, Idalia; Rustici, Gabriella et al. (2006) Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood 108:4126-35
|
Showing the most recent 10 out of 47 publications
